Alexium International Group Limited (ASX:AJX) develops and commercializes proprietary performance chemicals for advanced materials applications, focusing on flame retardancy, thermal regulation, and protective treatments for textiles, foams, bedding, military gear, upholstery, and related sectors; its core products include AlexiCool and BioCool microencapsulated phase change materials (mPCM) for cooling fabrics and bedding in slurry, cake, and dry powder formats, Eclipsys perpetual cooling technology, AlexiFlam environmentally friendly flame retardant treatments for cellulosic textiles including cotton and linen used in mattresses, workwear, and apparel, AlexiGuard protective solutions, AlexiShield flame-resistant coatings and barriers such as FR socks that meet 16 CFR 1633 standards, and custom formulations for specific industry challenges. The Australia-listed company, founded in 2009 through acquisition of U.S. Air Force-developed Reactive Surface Treatment technology and listed on the ASX in 2010, maintains headquarters in Greer, South Carolina, with additional operations in Melbourne, Victoria, Australia, and generates majority revenue from the United States while pursuing expansion in Europe, Asia-Pacific, and Latin America through customer diversification, international qualifications for mPCM and flame-retardant products, and penetration of Australasian and Southeast Asian bedding markets. In recent developments, Alexium advances full-scale production of high-solids mPCM slurries and dry powders to support FY26 sales growth, launches AlexiShield FR socks passing key U.S. mattress burn tests amid regulatory changes banning hazardous substances, secures a second tranche of U.S. military funding for AlexiFlam flame-retardant nylon/cotton uniforms emphasizing fire protection and breathability, amends its asset-based line of credit with Alterna Capital Solutions through February 2026 and draws shareholder loans totaling US$1.67 million from Colinton Capital Partners and Wentworth Williamson maturing September 2026 to bolster working capital amid Q4 FY25 sales of US$0.8 million and ongoing mattress market contraction, while positioning for recovery via U.S. tariffs favoring domestic suppliers and forecasted 2025-2026 industry unit shipment increases.